Clinical Trial Update: The Study of CIK Plus S-1 and Bevacizumab as Maintenance Treatment for Patients With Advanced Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating maintenance therapy with CIK cells plus S-1 and bevacizumab in patients with advanced colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CIK cells (cytokine-induced killer cells) (cytokine-induced killer cells)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: The First People's Hospital of Changzhou | Conditions: Colorectal Neoplasms | Phase 2 | Status: ACTIVE_NOT_RECRUITING